Evaluation of the efficacy of pidotimod in the exacerbations in patients affected with chronic bronchitis.

医学 慢性支气管炎 安慰剂 支气管炎 内科学 临床试验 病理 替代医学
作者
A Bisetti,G Ciappi,F Bariffi,E Catena,Rocco Tripodi,L Vaccaro,Grassi,G Scarpazza,Luigi F. Bertoli,Anna Cardani
出处
期刊:PubMed 卷期号:44 (12A): 1499-502 被引量:5
链接
标识
摘要

The efficacy and safety of pidotimod ((R)-3-[(S)-(5-oxo-2-pyrrolidinyl)carbonyl]-thiazolidine-4-carboxylic acid, PGT/1A, CAS 121808-62-6), a new oral synthetic immunostimulating agent, were investigated in a multicentre study, performed in 10 university and hospital centres of pneumophthisiology and respiratory physiopathology, according to a double-blind vs. placebo experimental design. Primary objective of the investigation was to verify the efficacy of pidotimod against infectious exacerbations in patients affected with chronic bronchitis. 181 inpatients or outpatients (117 male, 64 female; mean age: 62.5 years), affected with chronic bronchitis, were enrolled in the study. Pidotimod 800 mg/die or placebo sachets were administered by oral route for 60 consecutive days, followed by a 60-day follow-up period. Clinical observations were performed at baseline (D 0), after 30 (D 30) and 60 (D 60) days of treatment, as well as at the end of the follow-up (D 120). Time and frequency of infectious relapses were considered as the target variable for the evaluation of the efficacy of the drug. Clinical picture, expectoration characteristics, spirometric parameters and laboratory tests were monitored to evaluate patients' conditions. The results indicate that pidotimod is significantly more effective than placebo against infectious relapses in patients suffering from chronic bronchitis. During the first month, 9% of patients treated with pidotimod were affected with an infectious relapse vs. 39.5% of patients treated with placebo (chi 2, p < 0.001). In the second month, infectious episodes were reported by 1.2% of patients treated with the drug vs. 46.1% of patients treated with placebo (chi 2, p < 0.001).(ABSTRACT TRUNCATED AT 250 WORDS)

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
liu完成签到,获得积分10
1秒前
1秒前
1秒前
4秒前
4秒前
咎冷亦完成签到,获得积分10
4秒前
nonononono发布了新的文献求助10
4秒前
封印完成签到,获得积分10
6秒前
6秒前
dehua发布了新的文献求助10
6秒前
7秒前
8秒前
诗轩发布了新的文献求助10
9秒前
dzy1317发布了新的文献求助10
9秒前
单纯的手机完成签到,获得积分10
10秒前
xiyu666完成签到 ,获得积分10
11秒前
cat发布了新的文献求助10
11秒前
川川完成签到,获得积分10
12秒前
幸运海星发布了新的文献求助30
12秒前
12秒前
13秒前
13秒前
尹博士应助科研通管家采纳,获得10
14秒前
cocolu应助科研通管家采纳,获得10
14秒前
斯文败类应助科研通管家采纳,获得10
14秒前
在水一方应助科研通管家采纳,获得10
14秒前
Ava应助科研通管家采纳,获得10
14秒前
alter_mu应助科研通管家采纳,获得30
14秒前
orixero应助科研通管家采纳,获得10
15秒前
在水一方应助科研通管家采纳,获得10
15秒前
15秒前
小蘑菇应助科研通管家采纳,获得10
15秒前
在水一方应助科研通管家采纳,获得10
15秒前
Hello应助科研通管家采纳,获得10
15秒前
情怀应助科研通管家采纳,获得10
15秒前
小马甲应助科研通管家采纳,获得10
15秒前
15秒前
15秒前
兮豫完成签到 ,获得积分10
17秒前
芯茶完成签到 ,获得积分10
17秒前
高分求助中
歯科矯正学 第7版(或第5版) 1004
Smart but Scattered: The Revolutionary Executive Skills Approach to Helping Kids Reach Their Potential (第二版) 1000
Semiconductor Process Reliability in Practice 720
PraxisRatgeber: Mantiden: Faszinierende Lauerjäger 700
Mesopotamian divination texts : conversing with the gods : sources from the first millennium BCE 500
The Heath Anthology of American Literature: Early Nineteenth Century 1800 - 1865 Vol. B 500
A new species of Velataspis (Hemiptera Coccoidea Diaspididae) from tea in Assam 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3223177
求助须知:如何正确求助?哪些是违规求助? 2871898
关于积分的说明 8177369
捐赠科研通 2538751
什么是DOI,文献DOI怎么找? 1370791
科研通“疑难数据库(出版商)”最低求助积分说明 645870
邀请新用户注册赠送积分活动 619844